Drug Repurposing

Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., et al. (2019). Drug Repurposing: Progress, Challenges and Recommendations. Nature Reviews Drug Discovery, 18(1).

Type

Journal article

Intellectual base

Primary research

Year

2019

DOI

10.1038/nrd.2018.168

Link

https://doi.org/10.1038/nrd.2018.168

Cited from

organizational_management

Cited by

2 citations across 2 artifacts.

Each citation links to the sentence it supports in the citing article.

Primes

• Adaptive Redirection
  • In pharmaceutical development the channel is a safety database, a manufacturing and stability package, and a validated assay, and a compound that fails in one indication carries all three into another.

    This sourceDocuments that repurposed compounds are de-risked by existing safety, pharmacokinetic and formulation/manufacturing packages and can therefore enter development at a later phase, with shorter timelines and lower cost than a fresh programme.

Domain-specific

• Drug Repositioning
  • Identification is only the beginning: a predicted drug–disease link must survive mechanistic, preclinical, clinical, regulatory, manufacturing, safety, and commercial evaluation.

Verification

This reference passed the adversarial substantiation pipeline: it was checked to exist and to support the claim it is attached to. See how references were verified.

Registry ID ref:92eab5c1cc12 · see in the full table